irinotecan has been researched along with Intestinal Diseases in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, QL; Jia, HJ; Rui Bai, S; Wang, XB; Xia, J; Yue He, S; Zhou, M | 1 |
| Deng, H; Dou, W; Pan, Y; Wang, Y; Xiao, L; Xu, H | 1 |
| Huang, H; Jiang, W; Jinbo, M; Wang, H; Wang, X; Yu, P; Zhang, G; Zhang, X | 1 |
| Chang, XY; Dong, L; Jiang, ZP; Jin, WY; Li, ZZ; Shi, JW; Shi, Y; Sun, H; Wu, JS | 1 |
| Hirao, J; Iguchi, T; Mori, K; Nishiya, T; Saitoh, W; Shirai, M; Takada, S; Tsuji, M | 1 |
| Chen, S; Feng, M; Guo, S; Hou, Q; Liu, Y; Pan, Y; Sun, L; Wang, P; Wang, Y; Xu, H; Yue, T | 1 |
| Brunner, T; Grabinger, T; Kostadinova, F; Leist, M; Luks, L; Medema, JP; Zimberlin, C | 1 |
| Almeida, PR; Batista, GL; Bem, AX; Borges, VF; Brito, GA; Carvalho, CB; Cunha, FQ; Cunha, TM; Leite, CA; Lima-Júnior, RC; Ribeiro, RA; Silva, RL; Teixeira, MA; Wanderley, CW; Wong, DV | 1 |
| Cunha, FQ; Leite, CA; Lima-Júnior, RC; Mota, JM; Ribeiro, RA; Souza, MH; Wanderley, CW; Wong, DV | 1 |
| Chang, HJ; Choi, HS; Jeong, SY; Kim, DY; Kim, SY; Oh, JH; Park, JW; Seo, GJ; Shin, A; Yoo, SB | 1 |
| Chan, E; Chan, SY; Chen, X; Duan, W; Ho, PC; Hu, Z; Huang, M; Li, X; Xu, C; Yang, H; Yang, X; Zhou, S; Zhu, YZ | 1 |
| Cuzzocrea, S; Dorio, AS; Forini, O; Graziani, G; Lapidus, R; Leonetti, C; Mazzon, E; Muzi, A; Scarsella, M; Tentori, L; Vergati, M; Xu, W; Zhang, J | 1 |
| Fidler, IJ; Killion, JJ; Kumar, R; Kuniyasu, H; Shinohara, H | 1 |
| Atsumi, R; Hakusui, H; Suzuki, W | 1 |
1 review(s) available for irinotecan and Intestinal Diseases
| Article | Year |
|---|---|
Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cytokines; Fluorouracil; Humans; Intestinal Diseases; Irinotecan; Mucositis; Receptors, Cytokine | 2016 |
13 other study(ies) available for irinotecan and Intestinal Diseases
| Article | Year |
|---|---|
Artesunate ameliorates irinotecan-induced intestinal injury by suppressing cellular senescence and significantly enhances anti-tumor activity.
Topics: Animals; Artesunate; Camptothecin; Cellular Senescence; Humans; Intestinal Diseases; Irinotecan; Mice; Neoplasms; TOR Serine-Threonine Kinases | 2023 |
Treatment with S-adenosylmethionine ameliorates irinotecan-induced intestinal barrier dysfunction and intestinal microbial disorder in mice.
Topics: Animals; Caco-2 Cells; Diarrhea; Gastrointestinal Diseases; Humans; Intestinal Diseases; Intestinal Mucosa; Irinotecan; Mice; Occludin; S-Adenosylmethionine; Tight Junctions | 2023 |
Ganciclovir reduces irinotecan-induced intestinal toxicity by inhibiting NLRP3 activation.
Topics: Animals; Antiviral Agents; Apoptosis; Biomarkers; Cell Proliferation; Colonic Neoplasms; Diarrhea; Ganciclovir; Gene Expression Regulation; Humans; Inflammation; Intestinal Diseases; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NLR Family, Pyrin Domain-Containing 3 Protein; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Identification of the bioactive components of Banxia Xiexin Decoction that protect against CPT-11-induced intestinal toxicity via UPLC-based spectrum-effect relationship analyses.
Topics: Animals; Chromatography, High Pressure Liquid; Diarrhea; Drugs, Chinese Herbal; Female; Intestinal Diseases; Irinotecan; Mice; Mice, Inbred ICR; Tandem Mass Spectrometry; Topoisomerase I Inhibitors | 2021 |
Plasma citrulline is a sensitive safety biomarker for small intestinal injury in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Arginine; Biomarkers; Camptothecin; Citrulline; Down-Regulation; Ileum; Intestinal Diseases; Irinotecan; Jejunum; Male; Metabolomics; Rats, Sprague-Dawley; Time Factors | 2018 |
The administration of Escherichia coli Nissle 1917 ameliorates irinotecan-induced intestinal barrier dysfunction and gut microbial dysbiosis in mice.
Topics: Animals; Caco-2 Cells; Claudin-1; Diarrhea; Dysbiosis; Escherichia coli; Gastrointestinal Diseases; Gastrointestinal Microbiome; Humans; Intestinal Diseases; Intestinal Mucosa; Intestines; Irinotecan; Male; Mice; Mice, Inbred BALB C; Probiotics; Tight Junction Proteins | 2019 |
Ex vivo culture of intestinal crypt organoids as a model system for assessing cell death induction in intestinal epithelial cells and enteropathy.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Biological Assay; Caco-2 Cells; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Epithelial Cells; Humans; Intestinal Diseases; Intestinal Mucosa; Intestine, Small; Irinotecan; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Organoids; Proto-Oncogene Proteins; Time Factors; Tumor Necrosis Factor-alpha | 2014 |
The Adaptor Protein Myd88 Is a Key Signaling Molecule in the Pathogenesis of Irinotecan-Induced Intestinal Mucositis.
Topics: Animals; Bacteremia; Camptothecin; Diarrhea; Intestinal Diseases; Intestinal Mucosa; Irinotecan; Mice; Mice, Knockout; Mucositis; Myeloid Differentiation Factor 88; Peroxidase; Signal Transduction; Toll-Like Receptor 2; Toll-Like Receptor 9 | 2015 |
Intestinal complications after palliative treatment for asymptomatic patients with unresectable stage IV colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Incidence; Intestinal Diseases; Irinotecan; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Postoperative Complications; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Blood Cell Count; Body Weight; Camptothecin; Chromatography, High Pressure Liquid; Diarrhea; Drug Interactions; Half-Life; Hypericum; Intestinal Diseases; Intestinal Mucosa; Irinotecan; Male; Rats; Rats, Sprague-Dawley; Reference Standards; Reproducibility of Results | 2005 |
Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Proliferation; Colonic Neoplasms; Colony-Forming Units Assay; Dacarbazine; Diarrhea; Drug Synergism; Enzyme Inhibitors; Intestinal Diseases; Irinotecan; Organic Chemicals; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Topoisomerase I Inhibitors; Tumor Burden | 2006 |
Prevention of intestinal toxic effects and intensification of irinotecan's therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002.
Topics: Adjuvants, Immunologic; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Drug Synergism; Intestinal Diseases; Irinotecan; Lipopeptides; Lipoproteins; Liver Neoplasms, Experimental; Macrophage Activation; Macrophages; Mice; Mice, Inbred BALB C | 1998 |
Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion.
Topics: Animals; Bile; Biotransformation; Camptothecin; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Enterohepatic Circulation; Feces; Glucuronidase; Hydrolysis; Intestinal Diseases; Irinotecan; Lactones; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Rats; Rats, Inbred Strains; Spectrometry, Fluorescence | 1991 |